While life below the top tier of biotech is focused on survival rather than revival, Cephalon Inc. is plotting its escape from investor purgatory by creating a profitable specialty pharmaceutical company with critical mass achieved through acquisitions.

Investors presumably like the plan, as they just bought up CEPH's offering of $100 million in convertible exchangeable preferred stock last week (see Ebb & Flow, A12).